Global Healthcare Weekly Investor Views
09/27/2010

Live Video Every Wednesday at 15:00 LONDON at www.3bnexus.com

Online PR News – 27-September-2010 – – Global Life Science veteran and former fund manager of the Axa Framlington Biotech Fund, Schroder Ventures and 3i, Dr. Andy Smith, looks at the current issues surrounding biotech and pharma companies.

In his first talk, Andy discusses valuations of profitable companies relative to history. The discussion explores the PE values of various companies and how these have changed over time.

Andy will be giving a weekly video webcast on various aspects of the biotech space at 3B NEXUS business and investor video portal. Your clients might be interested to hear Andy's views and conclusions on the topics covered.

Here is the schedule of the confirmed weekly topics:

Speaker: Dr. Andy Smith
Date/Time: Every Wednesday at 1500 LONDON time
Place: Visit www.3bnexus.com to watch live followed immediately on-demand video

22 September 2010 @ 1500 LONDON Valuations - Current Issues In Biotech And Pharma

29 September 2010 @ 1500 LONDON Clinical trials and Cancer, the lessons, paradoxes and positives
06 October 2010 @ 1500 LONDON Vaccines, Investment and the Future
13 October 2010 @ 1500 LONDON New Antibiotics
20 October 2010 @ 1500 LONDON Cancer Vaccines
27 October 2010 @ 1500 LONDON Neuroscience, a headache or pain for investors?

New topics will be confirmed at a later date. Join the discussion and leave your comments, feedback and suggestions for more on this and other upcoming Global Healthcare sector topics.

Dr. Andy Smith's profile and video transcript will also be available for download.

You can broadcast live or upload your own investor and corporate videos. Free WebTV for your websites and targeted marketing is provided by 3B NEXUS.

Marketing Contact:
Esther V. Shire
Marketing Executive
3B NEXUS Limited
Tel: +44 (0) 845 617 1010
Fax: +44 (0) 845 617 1012
Email: marketing@3bnexus.com
Visit: www.3bnexus.com

The live and On-Demand video platform and portal for business and investor communications plus Targeted Marketing.